Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
1.049
-0.021 (-1.93%)
Nov 21, 2024, 12:45 PM EST - Market open
Indaptus Therapeutics Employees
Indaptus Therapeutics had 7 employees as of December 31, 2023. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,127,680
Market Cap
10.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 1 | 16.67% |
Dec 31, 2022 | 6 | 1 | 20.00% |
Dec 31, 2021 | 5 | 3 | 150.00% |
Dec 31, 2020 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
PAVmed | 107 |
ImmunoPrecise Antibodies | 101 |
MSP Recovery | 88 |
Turnstone Biologics | 80 |
BiomX | 71 |
Dominari Holdings | 28 |
Talphera | 15 |
COSCIENS Biopharma | 12 |
INDP News
- 10 days ago - Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - GlobeNewsWire
- 14 days ago - Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 8 months ago - Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 9 months ago - Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort - GlobeNewsWire